HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Epithelial ovarian cancers (EOCs) often exhibit morphologic features of embryonic Müllerian duct-derived tissue lineages and colonize peritoneal surfaces that overlie connective and adipose tissues. However, the mechanisms that enable EOC cells to readily adapt to the peritoneal environment are poorly understood. In this study, we show that expression of HOXA9, a Müllerian-patterning gene, is strongly associated with poor outcomes in patients with EOC and in mouse xenograft models of EOC. Whereas HOXA9 promoted EOC growth in vivo, HOXA9 did not stimulate autonomous tumor cell growth in vitro. On the other hand, expression of HOXA9 in EOC cells induced normal peritoneal fibroblasts to express markers of cancer-associated fibroblasts (CAFs) and to stimulate growth of EOC and endothelial cells. Similarly, expression of HOXA9 in EOC cells induced normal adipose- and bone marrow-derived mesenchymal stem cells (MSCs) to acquire features of CAFs. These effects of HOXA9 were due in substantial part to its transcriptional activation of the gene encoding TGF-β2 that acted in a paracrine manner on peritoneal fibroblasts and MSCs to induce CXCL12, IL-6, and VEGF-A expression. These results indicate that HOXA9 expression in EOC cells promotes a microenvironment that is permissive for tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secretion of elevated levels of IL-6 by MSC has been detected upon interaction with malignant cells in several epithelial, hematopoietic and mesenchymal cancers (Table 2) [43, 69, 76, 77, 82, 115–119].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516 · cited 2×
“Overexpression of Hoxa9 in primary bone marrow cells enhances hematopoietic stem cell regeneration, expands the myeloid progenitor pool, and collaborates with Meis1a to induce AML in mice (52, 53).”
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · cited 1×
“Because TGF-β signaling induces EMT in many cell types (31), CAFs in +HOXA9 tumors might also derive from tumor cells.”
Human Adipose Tissue Is a Source of Multipotent Stem Cells
Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., & Hedrick, M. H. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-02-0105 · Cited by 6,664 · cited 2×
“Bone marrow is the most well-characterized source of MSCs, but MSCs reside in most tissues and are abundant in white adipose tissues (23, 24).”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 11×
“A similar difference in FAP induction was also observed (Supplemental Figure 7B).”
InfluentialOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Mesenchymal stem cells reside in virtually all post-natal organs and tissues
Meirelles, L. D. S., Chagastelles, P. C., & Nardi, N. B. (2006) · Journal of Cell Science · doi:10.1242/jcs.02932 · Cited by 2,485 · cited 1×
“Bone marrow is the most well-characterized source of MSCs, but MSCs reside in most tissues and are abundant in white adipose tissues (23, 24).”
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672 · cited 3×
“However, since progression of EOC is driven by multiple autocrine and paracrine mechanisms (1, 2), we cannot exclude the possibility that HOXA9 also promotes progression of this disease by stimulating other signaling pathways in tumor or host cells.”
Self-citationNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467 · cited 3×
“Tothill et al. classified tumors in the AOCS cohort into molecular subtypes by their gene expression signatures (19).”
InfluentialSanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447
Stenderup, K. (2003) · Bone · doi:10.1016/j.bone.2003.07.005 · Cited by 1,206
Cited by
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
“In ovarian cancer through TGF-β signaling pathway, tumor-derived lysophosphatidic acid and exosomes promoted the differentiation of MSCs to CAFs, and cancer-derived TGF-β stimulated the expression of IL-6, C–X-C motif chemokine 12 (CXCL12), and VEGFA in CAFs to induce metastasis.(114) Accumulating evidence suggests th…”
BackgroundRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum
Lee, W., Ko, S. Y., Mohamed, M. S., Kenny, H. A., Lengyel, E., & Naora, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181170 · Cited by 478
“ES2 cells that stably express tGFP have been previously described (Ko et al., 2012).”
BackgroundSelf-citationGuo, F., Wang, Y., Liu, J., Mok, S. C., Xue, F., & Zhang, W. (2016) · Oncogene · doi:10.1038/onc.2015.139 · Cited by 468
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
“These molecules include IL-10, type I IFNs, IDO, adenosine, VEGF-A, TGF-β, and IL-35.”
BackgroundInfluentialYoshida, G. J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01611-0 · Cited by 316
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12392 · Cited by 280
“Homeobox A9 in ovarian cancer cells stimulated BM-MSCs to differentiate into CAFs by activating TGF-β2 transcription [30].”
BackgroundThe CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Daniel, S. K., Seo, Y. D., & Pillarisetty, V. G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.007 · Cited by 239
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Epithelial ovarian cancer experimental models
Lengyel, E., Burdette, J. E., Kenny, H. A., Matei, D., Pilrose, J., Haluska, P., Nephew, K. P., Hales, D. B., & Stack, M. S. (2014) · Oncogene · doi:10.1038/onc.2013.321 · Cited by 208
Self-citationMikuła-Pietrasik, J., Uruski, P., Tykarski, A., & Książek, K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2663-1 · Cited by 197
“Simultaneously, it is not entirely clear what the exact origin of CAFs within the peritoneal tumors is; what is known for sure is that they do not derive from the cancer cells [128].”
BackgroundThibault, B., Castells, M., Delord, J.-P., & Couderc, B. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9456-2 · Cited by 184
“Neoangiogenesis is consecutive to secretions of proangiogenic factors, like cytokines and growth factors, by both tumor cells and microenvironment cells, such as carcinomaassociated fibroblasts (CAFs) and mesenchymal stem cells (MSCs) [137].”
BackgroundInfluentialMesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“Yet, both BM-MSC and subcutaneous adipose-derived MSC can acquire a TAF phenotype in presence of ovarian cancer cells [69].”
BackgroundLin, S., Liao, Y.-C., Chen, P., Yang, Y., Wang, Y., Tung, S.-L., Chuang, C.-M., Sung, Y.-W., Jang, T., Chuang, S., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00888-x · Cited by 167
“Further, normal peritoneal fibroblasts that are located in the tumor microenvironment can be activated to express CAF markers that enhance ovarian cancer cell and endothelial cells growth [14].”
BackgroundCarcinoma-associated fibroblasts provide operational flexibility in metastasis
Wever, O. D., Bockstal, M. V., Mareel, M., Hendrix, A., & Bracke, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.009 · Cited by 151
Zhou, L., Wang, Y., Zhou, M., Zhang, Y., Wang, P., Li, X., Yang, J., Wang, H., & Ding, Z. (2018) · Nature Communications · doi:10.1038/s41467-018-03914-5 · Cited by 147
“Fanconi anemia pathway (16) AMPK signaling pathway (30) TNF signaling pathway (40) NF-kappa B signaling pathway (37) Osteoclast differentiation (40) B cell receptor signaling pathway (25) Melanoma (23) HIF-1 signaling pathway (32) p53 signaling pathway (22) mTOR signaling pathway (23) Spliceosome (36) Legionellosis (3…”
Devaud, C., Westwood, J. A., John, L. B., Flynn, J. K., Paquet-Fifield, S., Duong, C. P., Yong, C. S., Pegram, H. J., Stacker, S. A., Achen, M. G., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.219 · Cited by 122
“Currently, the tumor microenvironment is known to be crucial in tumor development and its response to treatment (13,14).”
Tumor microenvironment in ovarian cancer peritoneal metastasis
Mei, S., Chen, X., Wang, K., & Chen, Y. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02854-5 · Cited by 131
“For example, fibroblasts could secrete TGF-β2, which can promote levels of CXCL12, IL-6 and VEGF-A, inducing immune evasion of cancer cells and angiogenesis [89].”
BackgroundGuo, Y., Kenney, S. R., Muller, C. Y., Adams, S. F., Rutledge, T. L., Romero, E., Murray-Krezan, C. M., Prekeris, R., Sklar, L. A., Hudson, L. G., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0419 · Cited by 124
Frassanito, M. A., Rao, L., Moschetta, M., Ria, R., Marzo, L. D., Luisi, A. D., Racanelli, V., Catacchio, I., Berardi, S., Basile, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.254 · Cited by 116
Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts
Heneberg, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.008 · Cited by 110
An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis
Zhao, L., Ji, G., Le, X., Luo, Z., Wang, C., Feng, M., Xu, L., Zhang, Y., Lau, W. B., Lau, B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.487 · Cited by 110
Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Dasari, S., Fang, Y., & Mitra, A. K. (2018) · Cancers · doi:10.3390/cancers10110406 · Cited by 103
“Ovarian cancer cell expression HOXA9 induces CAFs to secrete CXCL12, IL-6, and VEGF-A expression, which promotes angiogenesis [87].”
BackgroundHussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 109
Homeobox Genes in Cancers: From Carcinogenesis to Recent Therapeutic Intervention
Feng, Y., Zhang, T., Wang, Y., Xie, M., Ji, X., Luo, X., Huang, W., & Xia, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770428 · Cited by 105
Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
Gupta, V., Yull, F., & Khabele, D. (2018) · Cancers · doi:10.3390/cancers10100366 · Cited by 91
“HOXA9 polarizes peritoneal macrophages to M2-like phenotypes [45].”
BackgroundOvarian cancer stem cells: Molecular concepts and relevance as therapeutic targets
Ahmed, N., Abubaker, K., & Findlay, J. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.06.002 · Cited by 94
Usui, A., Ko, S. Y., Barengo, N., & Naora, H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0489 · Cited by 97
“On the basis of our prior experience using mouse intraperitoneal xenograft models derived from SKOV3ip cells (17), the earliest time point at which peritoneal tumor implants can be detected in mice is at 10 days following tumor cell inoculation.”
MethodSelf-citationMetalloproteinases in Ovarian Cancer
Carey, P. M., Low, E. L., Harper, E. I., & Stack, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073403 · Cited by 87
“They can promote metastasis by stimulating peritoneal fibroblasts, mesenchymal stem cells, and tumor-associated macrophages through the expression of the HOXA9 gene [69] and xenograft studies show a correlation between high HOXA9 gene expression and increased ovarian tumor growth [70].”
BackgroundThe Role of Cancer-Associated Fibroblasts in Ovarian Cancer
Zhang, M., Chen, Z., Wang, Y., Zhao, H., & Du, Y. (2022) · Cancers · doi:10.3390/cancers14112637 · Cited by 92
“Then, the activated TGF-β2 may be able to induce CAF expression of CXCL12, IL-6, and VEGF-A to form a favorable microenvironment for EOC progression (Figure 3a) [63].”
BackgroundLee, W., Ko, S. Y., Akasaka, H., Weigert, M., Lengyel, E. R., & Naora, H. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.004 · Cited by 85
Self-citationThuwajit, C., Ferraresi, A., Titone, R., Thuwajit, P., & Isidoro, C. (2018) · Medicinal Research Reviews · doi:10.1002/med.21473 · Cited by 84
Ren, C., Cheng, X., Lu, B., & Yang, G. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.140 · Cited by 75
“It is clear that cancer-associated fibroblasts (CAF) are usually senescent, but they secrete a large amount of tumourigenic inflammatory cytokines and possess a prominent role in promoting tumour growth and progression [40–42].”
BackgroundYu, M., Zhan, J., & Zhang, H. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109469 · Cited by 75
Ko, S. Y., Ladanyi, A., Lengyel, E., & Naora, H. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.09.017 · Cited by 67
Self-citationMetabolic dependencies and targets in ovarian cancer
Zhang, Y., Wang, Y., Zhao, G., Oršulić, S., & Matei, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108413 · Cited by 75
Suh, D. H., Kim, H. S., Kim, B., & Song, Y. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.011 · Cited by 69
Beach, J. A., Aspuria, P.-J. P., Cheon, D., Lawrenson, K., Agadjanian, H., Walsh, C., Karlan, B. Y., & Oršulić, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6703 · Cited by 65
“Studies have shown that ovarian cancer cells are an abundant source of TGF-β, a potent inducer of fibroblast activation in cancer [8, 22, 25, 26].”
BRCA mutations in the manifestation and treatment of ovarian cancer
Pan, Z., & Xie, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18280 · Cited by 68
“Analysis of EOC tissues has also shown that the homeobox gene HOX9 is up-regulated and this results in a more permissive environment for tumor growth and development through its effect on the differentiation of Cancer associated fibroblasts (CAF) [49].”
BackgroundMotohara, T., Yoshida, G. J., & Katabuchi, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.038 · Cited by 60
The Role of the Tumor Stroma in Ovarian Cancer
Davidson, B., Tropé, C. G., & Reich, R. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00104 · Cited by 58
“HOXA9 expression in OC cells induced normal peritoneal fibroblasts and adipose tissueand bone marrow-derived mesenchymal cells to develop CAF features, a process shown to be mediated by TGF-β2 upregulation of CXCL12, IL-6, and VEGF-A (96).”
BackgroundWang, K., Jin, J., Ma, T., & Zhai, H. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13282 · Cited by 61
“asserted that the HOXA9 expression in epithelial ovarian cancer cells promised a comfortable environment for tumour growth [55].”
BackgroundImmunological configuration of ovarian carcinoma: features and impact on disease outcome
Fucikova, J. P., Coosemans, A., Oršulić, S., Cibula, D., Vergote, I. B., Galluzzi, L., & Špíšek, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002873 · Cited by 62
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer
Ribeiro, J. R., & Freiman, R. N. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.02.010 · Cited by 60
Homeobox Gene Deregulation: Impact on the Hallmarks of Cancer
Haria, D., & Naora, H. (2013) · Cancer Hallmarks · doi:10.1166/ch.2013.1007 · Cited by 58
“HOXA9-induced, tumor-derived TGF-β2 acted in a paracrine manner on peritoneal fibroblasts and MSCs and induced these cells to express mitogenic and pro-inflammatory growth factors (Ko et al., 2012).”
BackgroundInfluentialSelf-citationYue, H., Wang, J., Chen, R., Hou, X., Li, J., & Lü, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-6470-y · Cited by 62
Li, Y., Wang, L., Ma, W., Wu, J., Wu, Q., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06744-4 · Cited by 58
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Wang, Y., Zhu, N., Liu, J., Chen, F., Song, Y., Ma, Y., Yang, Z., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06508-0 · Cited by 56
Fang, Z., Xu, J., Zhang, B., Wang, W., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00988-x · Cited by 49
Targeting the Microenvironment in High Grade Serous Ovarian Cancer
Nwani, N. G., Sima, L. E., Nieves‐Neira, W., & Matei, D. E. (2018) · Cancers · doi:10.3390/cancers10080266 · Cited by 50
“In a transgenic mouse model, targeted depletion of FAP-expressing CAFs resulted in increased cancer cell death.”
BackgroundInfluentialPeng, Y., Li, Z., Yang, P., Newton, I. P., Ren, H., Zhang, L., Wu, H., & Li, Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.074 · Cited by 45
Overcoming cancer treatment resistance: Unraveling the role of cancer-associated fibroblasts
Wang, X., Zhou, Y., Wang, Y., Yang, J., Li, Z., Liu, F. L., Wang, A., Gao, Z., Wu, C. H., & Yin, H. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.03.002 · Cited by 51
Molecular implications of HOX genes targeting multiple signaling pathways in cancer
Shenoy, U. S., Adiga, D., Kabekkodu, S. P., Hunter, K. D., & Radhakrishnan, R. A. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09657-2 · Cited by 42
Ko, S. Y., & Naora, H. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-170 · Cited by 40
“We have identified that high HOXA9 expression is strongly associated with poor overall survival of EOC patients [10].”
BackgroundMethodSelf-citationMinimax rate-optimal estimation of high-dimensional covariance matrices with incomplete data
Cai, T., & Zhang, A. R. (2016) · Journal of Multivariate Analysis · doi:10.1016/j.jmva.2016.05.002 · Cited by 40
“The gene and miRNA expression markers affect each other through different mechanisms, the cross-covariances between the gene and miRNA markers are of significant interest (see Ko et al. [19]).”
BackgroundChen, J., Wang, Y., Zhang, W., Zhao, D., Zhang, L., Zhang, J., Fan, J., & Zhan, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.472 · Cited by 40
Niskakoski, A., Kaur, S., Staff, S. M., Renkonen‐Sinisalo, L., Lassus, H. J., Järvinen, H., Mecklin, J., Bützow, R. C., & Peltomäki, P. (2014) · Epigenetics · doi:10.4161/15592294.2014.983374 · Cited by 38
Gao, T., Yu, Y., Cong, Q., Wang, Y., Sun, M., Yao, L., Xu, C., & Jiang, W. (2018) · BMC Cancer · doi:10.1186/s12885-018-4918-0 · Cited by 34
Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter
Feng, S., Ding, B., Dai, Z., Yin, H., Ding, Y., Liu, S., Zhang, K., Lin, H. R., Xiao, Z., & Shen, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05085-y · Cited by 33
“Studies have highlighted the significance of transforming growth factor beta (TGF-β) signaling in promoting OC progression through its interaction with CAFs [10, 11].”
BackgroundSun, Q., Zhang, S.-Y., Zhao, J., Han, X., Wang, H., & Sun, M. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.12.045 · Cited by 33
“Of the 39 human HOX family members, HOXA9 was reported to be dysregulated in leukemia and in breast and ovarian cancers.(9,10,21) Interestingly, our findings showed that HOXA9 was highly expressed in HNSCC compared to their normal tissue counterparts, which was consistent with TCGA data.”
ResultmiR-652 Promotes Proliferation and Migration of Uveal Melanoma Cells by Targeting HOXA9
Xia, Z., Yang, C., Yang, X., Wu, S., Feng, Z., Qu, L., Chen, X., Liu, L., & Ma, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.917099 · Cited by 33
“In ovarian cancer, HOXA9 activated transcription of TGF-b2 to promote cancer progression [21].”
BackgroundRole of mesenchymal cells in the natural history of ovarian cancer: a review
Touboul, C., Vidal, F., Pasquier, J., Lis, R., & Rafii, A. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0271-5 · Cited by 33
“A genomic approach also correlates OCCs ability to induce CAFs features in MSCs with the expression of HOXA9, a Mullerian-patterning gene [87].”
BackgroundOvarian Cancer Dissemination—A Cell Biologist’s Perspective
Farsinejad, S., Cattabiani, T., Muranen, T. E., & Iwanicki, M. (2019) · Cancers · doi:10.3390/cancers11121957 · Cited by 34
Fogg, K. C., Renner, C. M., Christian, H., Walker, A., Marty‐Santos, L., Khan, A., Olson, W. R., Parent, C., O’Shea, A., Wellik, D. M., et al. (2020) · Tissue Engineering Part A · doi:10.1089/ten.tea.2020.0001 · Cited by 30
Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer
Bhardwaj, V., Zhang, X., Pandey, V., & Garg, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188888 · Cited by 31
Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance
Pasquier, J., & Rafii, A. (2012) · BioMed Research International · doi:10.1155/2013/630782 · Cited by 31
Human Ovarian Tissue Cortex Surrounding Benign and Malignant Lesions
Pavone, M. E., Hirshfeld‐Cytron, J., Tingen, C. M., Thomas, C., Thomas, J., Lowe, M. P., Schink, J. C., & Woodruff, T. K. (2013) · Reproductive Sciences · doi:10.1177/1933719113506498 · Cited by 30
“It is not clear how the ovarian environment influences the persistence of the primordial follicle pool, but we suspect that the relatively lower follicle counts seen around malignant lesions may be caused by elevated cytokines or other structural changes within the physical environment, including the neovascularizatio…”
BackgroundTumor-associated mesenchymal stem/stromal cells in tumor microenvironment and carcinogenesis
Sun, L., Cao, X., Zhou, B., Mei, J., Zhao, X., Li, Y., Yao, Y., & Wang, M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00688-7 · Cited by 33
“Subsequent studies have consistently reported MSCs as significant contributors to CAF populations in various tumors, including colon cancer [136, 137], ovarian cancer [138, 139], prostate cancer [140, 141], and others.”
Haria, D., Trinh, B. Q., Ko, S. Y., Barengo, N., Liu, J., & Naora, H. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.04.004 · Cited by 39
Self-citationSulaiman, R. A., De, P. K. R., Aske, J. C., Lin, X., Dale, A., Koirala, N., Gaster, K., Espaillat, L. R., Starks, D. C., & Dey, N. (2023) · Biomedicines · doi:10.3390/biomedicines11010112 · Cited by 27
“In ovarian cancers specifically, CAFs can induce angiogenesis through the secretion of IL-6, COX-2, and CXCL1 [60], while ovarian cancer cells are reported to induce CAFs to secrete CXCL12, IL-6, and VEGF-A expression via HOXA9, leading to angiogenesis [61].”
BackgroundOncogenic and tumor suppressor function of MEIS and associated factors
Girgin, B., Alpaslan, M. K., & Kocabaş, F. (2020) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2006-25 · Cited by 26
“The overexpression of HOXA9 is associated with poor outcomes in EOC patients and Hoxa9 regulates the activation of cancer-associated fibroblasts by TGF-β2 in EOC cells (Ko et al., 2012).”
BackgroundHOXA9 transcription factor is a double-edged sword: from development to cancer progression
Shenoy, U. S., Adiga, D., Alhedyan, F. S., Kabekkodu, S. P., & Radhakrishnan, R. A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10159-2 · Cited by 26
“Ko et al. in 2012 reported that elevated expression of HOXA9 in epithelial ovarian cancer (EOC) contributes to angiogenesis and the generation of a microenvironment for tumor growth [ 77 ].”
BackgroundWen, K., Sung, P., Wu, A. T. H., Chou, P., Lin, J.-H., Huang, C. F., Yeung, S. J., & Lee, M. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00703-x · Cited by 27
Nakanishi, T., Koma, Y., Miyako, S., Torigoe, R., Yokoo, H., Omori, M., Yamanaka, K., Ishihara, N., Tsukamoto, S., Kodama, T., et al. (2024) · Cells · doi:10.3390/cells13201733 · Cited by 27
“CAF-conditioned medium induces HOXA9 expression in epithelial ovarian cancer cells, leading to tumor-derived TGF-β 2 induction and differentiation of MSCs into CAFs, promoting tumor growth [14].”
BackgroundHendijani, F. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.10.015 · Cited by 27
Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma
Ando, H., Natsume, A., Senga, T., Watanabe, R., Ito, I., Ohno, M., Iwami, K., Ohka, F., Motomura, K., Kinjo, S., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2316-5 · Cited by 25
“1 3 transcriptionally activated by HOXa9 in cancer-associated fibroblasts, which results in the growth of ovarian cancer via the paracrine actions of CXCl12, Il-6, and VegF-a [17].”
BackgroundXu, L., Deng, Q., Pan, Y., Peng, M., Wang, X., Song, L., Xiao, M., & Wang, Z. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1549 · Cited by 30
“Numerous studies have found that cancer-associated fibroblasts (CAFs) play an important role in a wide variety of tumors, such as breast, prostate, esophageal, pancreatic and lung cancer by promoting the initiation, proliferation, invasion and metastasis of cancer cells; however, the underlying mechanisms are not yet…”
BackgroundOverexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells
Ju, T.-F., Jin, H., Ying, R., Xie, Q., Zhou, C., & Gao, D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6986 · Cited by 26
“Furthermore, HOXA9 expression levels in epithelial ovarian cancers cells have been demonstrated to induce cancer‐associated fibroblasts and promote a microenvironment permissive for tumor growth (24).”
BackgroundBilandzic, M., Wang, Y., Ahmed, N., Luwor, R. B., Zhu, H., Findlay, J. K., & Stenvers, K. L. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.039 · Cited by 25
The tumor immune microenvironment in peritoneal carcinomatosis
Demuytere, J., Ernst, S., van Ovost, J., Cosyns, S., & Ceelen, W. P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.015 · Cited by 23
Hahn, J. M., McFarland, K. L., Combs, K. A., Anness, M., & Supp, D. M. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12917 · Cited by 22
“HOXA9 overexpression is observed in some cancers, such as ovarian cancer and acute myeloid leukaemia, where its overexpression is associated with poor overall survival.(32,33) To overexpress HOXA9 in fibroblasts, keloid and normal fibroblasts (three donor strains each) were”
BackgroundMa, Y., Zhang, Y., Mou, X., Liu, Z., Ru, G., & Li, E. (2017) · Oncology Letters · doi:10.3892/ol.2017.6937 · Cited by 25
“Ko et al (20) identified that high expression of HOXA9 is associated with poor overall survival (OS) in ovarian cancer, and HOXA9 could promote ovarian tumor growth in vivo .”
InfluentialNaora, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00018 · Cited by 22
“In turn, TGF-β2 acted in a paracrine manner on omental fibroblasts and stimulated a TGF-β auto-regulatory loop in the stroma (46).”
BackgroundSelf-citationTherapeutic strategies for targeting the ovarian tumor stroma
Ko, S. Y., & Naora, H. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i6.194 · Cited by 21
Self-citationHOXA10 expression profiling in prostate cancer
Hatanaka, Y., Velasco, M. A. D., Oki, T., Shimizu, N., Nozawa, M., Yoshimura, K., Yoshikawa, K., Nishio, K., & Uemura, H. (2019) · The Prostate · doi:10.1002/pros.23761 · Cited by 19
“Other homeobox genes such as HOXA 9 have shown duplicitous roles exhibiting tumor promoting effects for ovarian cancer, but showing tumor suppressing activity in breast cancer.(31,32) HOXA10 is a homeobox gene that has also demonstrated context and cancer-specific roles.”
BackgroundRNA-based ovarian cancer research from ‘a gene to systems biomedicine’ perspective
Göv, E., Kori, M., & Arğa, K. Y. (2017) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2017.1330368 · Cited by 19
Demuytere, J., Ceelen, W. P., Dorpe, J. V., & Hoorens, A. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104442 · Cited by 18
Isolation of Fibroblast-Activation Protein-Specific Cancer-Associated Fibroblasts
Huang, Y., Zhou, S., Huang, Y., Zheng, D., Mao, Q., He, J., Wang, Y., Xue, D., Lü, X., Yang, N., et al. (2017) · BioMed Research International · doi:10.1155/2017/4825108 · Cited by 19
Fighting the force: Potential of homeobox genes for tumor microenvironment regulation
Northcott, J. M., Northey, J. J., Barnes, J. M., & Weaver, V. M. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.004 · Cited by 17
“Increased HoxA9 expression in ovarian cancer cells was shown to up-regulate transforming growth factor β2 (TGF-β2) and stimulate CAF secretion of pro-tumorigenic and pro-angiogenic factors (stromal cell-derived factor 1 (SDF-1, also known as CXCL12), interleukin 6 (IL-6) and VEGF) and promote immunosuppressive skewing…”
Verardo, R., Piazza, S., Klarić, E., Ciani, Y., Bussadori, G., Marzinotto, S., Mariuzzi, L., Cesselli, D., Beltrami, A. P., Mano, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1791 · Cited by 19
Piché, A. (2018) · World Journal of Clinical Oncology · doi:10.5306/wjco.v9.i8.167 · Cited by 17
Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope
Caron, J. M., Ames, J. J., Contois, L. W., Liebes, L., Friesel, R. E., Muggia, F. M., Vary, C., Oxburgh, L. H., & Brooks, P. C. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.015 · Cited by 17
Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
Khlebus, E., Vuttaradhi, V. K., Welte, T., Khurana, N., Celestino, J., Beird, H. C., Gumbs, C. E., Little, L., Legarreta, A. F., Fellman, B. M., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0623 · Cited by 16
“CAFs cells contribute to ovarian cancer initiation and development (57), cancer growth (58), and resistance to treatment (59).”
Jin, Y., Kim, H. K., Lee, J., Soh, E. Y., Kim, J.-H., Song, I., Chung, Y., & Choi, Y. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-43207-5 · Cited by 15
Self-citationThe many microenvironments of ovarian cancer
Micek, H. M., Visetsouk, M. R., Fleszar, A. J., & Kreeger, P. K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_12 · Cited by 14
Homeodomain protein DLX4 facilitates nasopharyngeal carcinoma progression via up‐regulation of YB‐1
Ling, Z., Long, X., Li, J., & Feng, M. (2020) · Genes to Cells · doi:10.1111/gtc.12772 · Cited by 23
“Dysregulation of homeoproteins has been shown to be associated with malignancies (Ko et al., 2012; Yuan et al., 2015).”
BackgroundCancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma
Affò, S., Sererols-Viñas, L., Garcia‐Vicién, G., Cadamuro, M., Chakraborty, S., & Sirica, A. E. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.07.009 · Cited by 12
Ko, S. Y., & Naora, H. (2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.379 · Cited by 12
“muscle actin (SMA) in ovarian cancer clinical specimens ([9]).”
InfluentialSelf-citationHOXA9 is a novel myopia risk gene
Liang, C.-L., Hsu, P., Ngo, C. S., Seow, W. J., Karnani, N., Pan, H., Saw, S., & Juo, S. H. (2019) · BMC Ophthalmology · doi:10.1186/s12886-019-1038-9 · Cited by 15
“Although there is no specific molecular marker for myopia, several molecules have been reported to be associated with myopia, which include TGF-β [24], FGF2 [35], IGF signaling [36, 37], HGF [38, 39] and MMP2 [40, 41].”
BackgroundInfluential
Metadata
- Authors
- Ko, S. Y., Barengo, N., Ladanyi, A., Lee, J.-S., Marini, F., Lengyel, E., & Naora, H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Wake Forest University (US)
- University of Chicago (US)
- Corresponding author
- Naora, Honami
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3603-3617
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3461910
- OpenAlex
- W1988224215
- Cited by
- 132
- References
- 62
- Citations by year
- 2025: 10 · 2024: 9 · 2023: 11 · 2022: 9 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 10 · 2016: 4 · 2015: 10 · 2014: 14 · 2013: 14 · 2012: 2
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (RP120390, 4r01ca111882-10)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (R01-CA111882, CA141078, CA101826, R01CA101826, R01CA141078, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- HOXA9, epithelial ovarian cancer, cancer-associated fibroblasts, tumor microenvironment, Müllerian ducts, TGF-beta2, mesenchymal stem cells, adipose-derived stem cells, bone marrow-derived stem cells, CXCL12, interleukin-6, VEGF-A, paracrine signaling, tumor growth
- MeSH terms
- Adipose Tissue, Animals, Carcinoma, Cell Differentiation, Cell Division, Epithelial Cells, Female, Fibroblasts, Humans, Mice, Nude, Neoplasm Proteins, Ovarian Neoplasms, Peritoneal Neoplasms, Peritoneum, Prognosis, Tumor Cells, Cultured, Interleukin-6, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Homeodomain Proteins, Paracrine Communication, Vascular Endothelial Growth Factor A, Endothelial Cells, Mice, Kaplan-Meier Estimate, Transforming Growth Factor beta2, Chemokine CXCL12, Tumor Microenvironment, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.